8-Bromo-cGMP (sodium)

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses[2].

[1]Sarkar O , et al. Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One. 2017 Jul 10;12(7):e0179301.|[2]Tegeder I , et al. Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett. 2002 Oct 31;332(2):146-50.|[3]Tobias Polte, et al. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med. 2002 Jan 1;32(1):56-63.|[4]Junzo Kamei, et al. Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 2005 Sep;117(1-2):112-20.|[5]Elza D van Deel, et al. Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1144-53.